Kieffer Tara Lynn 4

What Happened
Tara Lynn Kieffer, Enanta Pharmaceuticals' Chief Product Strategy Officer, received 6,562 shares of Enanta common stock on Feb 12, 2026 from the settlement of performance-based awards (1,575 shares and 4,987 shares). Those awards were issued at $0.00 per share (award settlement). To cover withholding taxes on the vesting, 3,257 shares were automatically forfeited (disposed) at a valuation of $14.25 per share, totaling $46,412. Net shares issued to Kieffer after withholding: 3,305 shares. This was the settlement of awards (not an open-market purchase or voluntary sale).

Key Details

• Transaction date: February 12, 2026; Form 4 filed Feb 13, 2026 (timely).
• Awards issued: 1,575 shares (PSUs) + 4,987 shares (rTSRU) = 6,562 shares at $0.00 acquisition price.
• Tax withholding: 3,257 shares withheld/disposed at $14.25 = $46,412.
• Net shares received: 3,305.
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: F1 = PSUs vested based on 2024–2025 R&D milestones; F2 = rTSRU settled based on relative total shareholder return vs. Nasdaq Biotech Index; F3 = shares automatically forfeited to cover withholding taxes.
• Transaction codes: A = award/grant; F = tax withholding/settlement.

Context
These were performance-based equity awards that vested and were settled in stock — common executive compensation rather than an open-market buy or sale. The rTSRU is a relative-TSR award tied to performance versus the Nasdaq Biotech Index over two-year periods; the PSU was tied to R&D milestones. Automatic share forfeiture to cover taxes is routine and does not necessarily indicate a discretionary sale by the insider.